Principal Securities, Inc. Arbutus Biopharma Corp Transaction History
Principal Securities, Inc.
- $4.47 Trillion
- Q1 2025
A detailed history of Principal Securities, Inc. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Principal Securities, Inc. holds 230 shares of ABUS stock, worth $729. This represents 0.0% of its overall portfolio holdings.
Number of Shares
230
Previous 230
-0.0%
Holding current value
$729
Previous $752,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ABUS
# of Institutions
190Shares Held
111MCall Options Held
866KPut Options Held
608K-
Morgan Stanley New York, NY23.8MShares$75.4 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.3MShares$42.2 Million27.3% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$36.6 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY9.47MShares$30 Million1.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.95MShares$28.4 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $475M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...